Please login to the form below

Not currently logged in
Email:
Password:

ocrelizumab

This page shows the latest ocrelizumab news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Tecentriq set for breast cancer filing, Ocrevus gets NICE thumbs down, NHS needs more cash

Daily Brief: Tecentriq set for breast cancer filing, Ocrevus gets NICE thumbs down, NHS needs more cash

NICE says no to Ocrevus in primary progressive MS. On Friday NICE announced that it would not recommend Roche; s Ocrevus (ocrelizumab) for treating primary progressive multiple sclerosis (PPMS) in adults. ... NICE also published draft guidance earlier

Latest news

More from news
Approximately 9 fully matching, plus 22 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics